Sign Up
OverviewAPI
Eli Lilly appoints new leaders for its diabetes and obesity unit ahead of a key decision on Mounjaro as a weight-loss treatment. The appointment comes as Lilly's shares have gained about 44% this year, driven by investor bets on the success of Mounjaro. Lilly raised its annual forecasts after beating estimates for quarterly results, driven by strong demand for its new diabetes drug Mounjaro. The company also announced that its experimental obesity drug, tirzepatide, met the main goals in two late-stage studies, with positive results for both diabetes and obesity.

Ask a question